Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Fortress Biotech's Debt-to-EBITDA or its related term are showing as below:
STU:CNB1'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.69 Med: -0.69 Max: 0.34
Current: 0.34
During the past 13 years, the highest Debt-to-EBITDA Ratio of Fortress Biotech was 0.34. The lowest was -3.69. And the median was -0.69.
STU:CNB1's Debt-to-EBITDA is ranked better than 73.44% of 305
companies
in the Biotechnology industry
Industry Median: 1.24
vs STU:CNB1: 0.34
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Fortress Biotech Debt-to-EBITDA Related Terms
Fortress Biotech Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Fortress Biotech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CNB1 vs ATRA, ICCC, PTHS: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Fortress Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortress Biotech Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortress Biotech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Fortress Biotech (STU:CNB1) has a Debt-to-EBITDA of 4.12 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Fortress Biotech. According to the industry distribution chart, Fortress Biotech ranks #81 out of 305 companies in the Biotechnology industry, placing it in the top 26.6%.
Is Fortress Biotech's Debt-to-EBITDA too high?
Fortress Biotech's current Debt-to-EBITDA is 4.12. The Biotechnology industry median Debt-to-EBITDA is 1.24. Fortress Biotech's value of 4.12 is 232.3% above this industry median. Based on the distribution chart, Fortress Biotech ranks #81 out of 305 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fortress Biotech has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Debt-to-EBITDA compare to ATRA and ICCC?
According to the Biotechnology industry distribution chart, Fortress Biotech ranks #81 out of 305 companies for Debt-to-EBITDA. This puts Fortress Biotech in the upper half of its industry. The industry median Debt-to-EBITDA is 1.24. Fortress Biotech's value of 4.12 is 232.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.24, based on 305 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortress Biotech's current Debt-to-EBITDA of 4.12 is 232.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Fortress Biotech. For the Biotechnology industry, the median Debt-to-EBITDA is 1.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortress Biotech's current Debt-to-EBITDA is 4.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Fortress Biotech (STU:CNB1) has a current Debt-to-EBITDA of 4.12. The stock's GF Value™ is €0.97, compared to a current price of €1.93 — trading 99% above its estimated fair value. The current Debt-to-EBITDA is 4.12 and 232.3% above the Biotechnology industry median of 1.24. Fortress Biotech's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Fortress Biotech (STU:CNB1), the current Debt-to-EBITDA is 4.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortress Biotech (STU:CNB1) Overvalued in 2026?
Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued.
The current stock price of €1.93 is trading 99% above its estimated GF Value™ of €0.97.
Key valuation signals for STU:CNB1:
Debt-to-EBITDA: 4.12
GF Value™: €0.97 vs. price of €1.93 (99% above fair value)
Industry Position: 232.3% above the Biotechnology median (#81 of 305)
No single metric tells the full story. See the STU:CNB1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
43GF Score
Get the complete analysis for STU:CNB1
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CNB1 has been successfully added to your 
